JP2016104735A - Melanogenesis inhibitor - Google Patents
Melanogenesis inhibitor Download PDFInfo
- Publication number
- JP2016104735A JP2016104735A JP2015229880A JP2015229880A JP2016104735A JP 2016104735 A JP2016104735 A JP 2016104735A JP 2015229880 A JP2015229880 A JP 2015229880A JP 2015229880 A JP2015229880 A JP 2015229880A JP 2016104735 A JP2016104735 A JP 2016104735A
- Authority
- JP
- Japan
- Prior art keywords
- bis
- oxo
- keratinocyte
- seq
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 56
- 230000003061 melanogenesis Effects 0.000 title abstract 3
- 210000001808 exosome Anatomy 0.000 claims abstract description 124
- 210000002510 keratinocyte Anatomy 0.000 claims abstract description 86
- 230000028327 secretion Effects 0.000 claims abstract description 46
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 37
- KCBIIRJHDAZURT-QRIPLOBPSA-N n-[(2r)-3-hydroxy-1-oxo-1-[(4-oxo-1-oxaspiro[2.5]octa-5,7-dien-7-yl)amino]propan-2-yl]decanamide Chemical compound O=C1C=CC(NC(=O)[C@@H](CO)NC(=O)CCCCCCCCC)=CC11OC1 KCBIIRJHDAZURT-QRIPLOBPSA-N 0.000 claims abstract description 28
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 27
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 26
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 26
- 208000012641 Pigmentation disease Diseases 0.000 claims abstract description 20
- 206010014970 Ephelides Diseases 0.000 claims abstract description 18
- 208000003351 Melanosis Diseases 0.000 claims abstract description 18
- 230000002087 whitening effect Effects 0.000 claims abstract description 17
- 230000002265 prevention Effects 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 230000003449 preventive effect Effects 0.000 claims abstract description 5
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 claims abstract 5
- 230000008099 melanin synthesis Effects 0.000 claims description 37
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 25
- 230000002829 reductive effect Effects 0.000 claims description 22
- NSFKAZDTKIKLKT-UHFFFAOYSA-N 3-[4-[3-[4-(4,5-dihydro-1h-imidazol-2-yl)anilino]-3-oxoprop-1-enyl]phenyl]-n-[4-(4,5-dihydro-1h-imidazol-2-yl)phenyl]prop-2-enamide;dihydrochloride Chemical compound Cl.Cl.C=1C=C(C=CC(=O)NC=2C=CC(=CC=2)C=2NCCN=2)C=CC=1C=CC(=O)NC(C=C1)=CC=C1C1=NCCN1 NSFKAZDTKIKLKT-UHFFFAOYSA-N 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 7
- 241000219051 Fagopyrum Species 0.000 claims description 4
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 50
- 239000000126 substance Substances 0.000 abstract description 25
- 210000003491 skin Anatomy 0.000 abstract description 23
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 230000019612 pigmentation Effects 0.000 abstract description 4
- KDQKMUCWBRINRA-UHFFFAOYSA-N 3-[4-[3-[4-(4,5-dihydro-1h-imidazol-2-yl)anilino]-3-oxoprop-1-enyl]phenyl]-n-[4-(4,5-dihydro-1h-imidazol-2-yl)phenyl]prop-2-enamide Chemical compound C=1C=C(C=CC(=O)NC=2C=CC(=CC=2)C=2NCCN=2)C=CC=1C=CC(=O)NC(C=C1)=CC=C1C1=NCCN1 KDQKMUCWBRINRA-UHFFFAOYSA-N 0.000 abstract description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 238000005282 brightening Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 72
- 210000002752 melanocyte Anatomy 0.000 description 43
- 230000000694 effects Effects 0.000 description 37
- 230000014509 gene expression Effects 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 26
- 239000002609 medium Substances 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 18
- 239000002953 phosphate buffered saline Substances 0.000 description 18
- 239000012228 culture supernatant Substances 0.000 description 14
- 102000003425 Tyrosinase Human genes 0.000 description 13
- 108060008724 Tyrosinase Proteins 0.000 description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
- 108010024636 Glutathione Proteins 0.000 description 12
- 229960003180 glutathione Drugs 0.000 description 12
- -1 serum Substances 0.000 description 12
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 108010051081 dopachrome isomerase Proteins 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 239000000654 additive Substances 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 9
- 210000001787 dendrite Anatomy 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 108010085238 Actins Proteins 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 5
- 102100025222 CD63 antigen Human genes 0.000 description 5
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 5
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 5
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 5
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 229940116978 human epidermal growth factor Drugs 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102100037904 CD9 antigen Human genes 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 4
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 4
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000003953 foreskin Anatomy 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 description 4
- PHOLIFLKGONSGY-CSKARUKUSA-N (e)-(3-methyl-1,3-benzothiazol-2-ylidene)hydrazine Chemical compound C1=CC=C2S\C(=N\N)N(C)C2=C1 PHOLIFLKGONSGY-CSKARUKUSA-N 0.000 description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 101150056978 HMGS gene Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 101100011891 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ERG13 gene Proteins 0.000 description 3
- 102100021461 Sphingomyelin phosphodiesterase 3 Human genes 0.000 description 3
- 101710201918 Sphingomyelin phosphodiesterase 3 Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
- 229960003942 amphotericin b Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 230000035806 respiratory chain Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102100040881 60S acidic ribosomal protein P0 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- MUWQRFNJDPFTBG-UHFFFAOYSA-N C=CC(N)=O.C=CC(N)=O.Cl.Cl Chemical compound C=CC(N)=O.C=CC(N)=O.Cl.Cl MUWQRFNJDPFTBG-UHFFFAOYSA-N 0.000 description 2
- 102100027221 CD81 antigen Human genes 0.000 description 2
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 2
- 101000673456 Homo sapiens 60S acidic ribosomal protein P0 Proteins 0.000 description 2
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 2
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- RWSXRVCMGQZWBV-UHFFFAOYSA-N L-Glutathione (reduced) Chemical compound OC(=O)C(N)CCC(=O)NC(CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-UHFFFAOYSA-N 0.000 description 2
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 108700031126 Tetraspanins Proteins 0.000 description 2
- 102000043977 Tetraspanins Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- JOOIICMXVKYRGU-UHFFFAOYSA-N prop-2-enamide;dihydrochloride Chemical compound Cl.Cl.NC(=O)C=C JOOIICMXVKYRGU-UHFFFAOYSA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 102000034342 Calnexin Human genes 0.000 description 1
- 108010056891 Calnexin Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 101000836492 Dictyostelium discoideum ALG-2 interacting protein X Proteins 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 101001134621 Homo sapiens Programmed cell death 6-interacting protein Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100033344 Programmed cell death 6-interacting protein Human genes 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 241001510071 Pyrrhocoridae Species 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 102100024550 Sphingomyelin phosphodiesterase 2 Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108700030796 Tsg101 Proteins 0.000 description 1
- 101150072717 Tsg101 gene Proteins 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000012574 advanced DMEM Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108040005466 neutral sphingomyelin phosphodiesterase activity proteins Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
Abstract
Description
本発明は、メラニン産生を抑制するメラニン産生抑制剤に関する。 The present invention relates to a melanin production inhibitor that suppresses melanin production.
人の皮膚や毛髪の色調は、皮膚及び毛髪に存在する色素メラニンの量によって決定される。メラニンは、皮膚や毛髪の毛球部に存在する色素細胞（メラノサイト）において、酵素チロシナーゼやドーパオキシダーゼによってチロシンから生合成されることから、メラノサイトの活性化又はチロシナーゼの活性化によりメラニン産生は亢進する。メラニン産生が亢進すると、皮膚は黒色化し、色素沈着やシミ・ソバカスが発生して、美容上の問題となる。 The color of human skin and hair is determined by the amount of pigment melanin present in the skin and hair. Melanin is biosynthesized from tyrosine by the enzyme tyrosinase or dopa oxidase in pigment cells (melanocytes) present in the hair bulb of the skin or hair, so that melanin production is enhanced by activation of melanocytes or activation of tyrosinase. When the production of melanin is increased, the skin becomes blackened, and pigmentation and spots and freckles occur, which is a cosmetic problem.
また、ケラチノサイトに存するメラニン顆粒は、メラノサイトで産生されたメラニン顆粒を、メラノサイトがデンドライトを伸長しケラチノサイトと接合して該メラニン顆粒をケラチノサイト内に転送することにより、ケラチノサイトに存するようになる。デンドライトの伸長が促進されてメラニン顆粒の転送が進むと、メラニン産生が促進し、皮膚が黒色化する。 Moreover, the melanin granule which exists in a keratinocyte comes to exist in a keratinocyte, when a melanocyte produces | generates a dendrite, joins with a keratinocyte, and this melanin granule transfers in a keratinocyte. When the extension of dendrites is promoted and the transfer of melanin granules proceeds, melanin production is promoted and the skin becomes black.
そこで、メラノサイトに直接作用して細胞増殖能及びメラニン産生能をはじめとした細胞活性を低下させることによりメラニン量を減少させたり、デンドライトの伸長を抑制する成分が見出されれば、皮膚の明色化（美白）、色素沈着やシミ・ソバカスの予防又は改善が実現できると考えられる。 Therefore, if a component that reduces the amount of melanin or suppresses dendrite elongation is found by directly acting on melanocytes to reduce cell activity such as cell proliferation ability and melanin production ability, lightening the skin (Whitening), prevention or improvement of pigmentation, spots and freckles can be realized.
一方、エクソソーム（ｅｘｏｓｏｍｅ）は脂質二重膜で囲まれた膜小胞で、従来は不要な細胞内成分を外に放出するために機能していると考えられてきたが、近年、免疫細胞や腫瘍細胞をはじめ、多くの細胞がエクソソームを放出し、これが分泌細胞（エクソソーム放出細胞）とその標的細胞（エクソソーム受容細胞）の間で蛋白質や脂質を交換する重要なメッセンジャーとなっていることが解明されつつある。近年、ケラチノサイト由来のエクソソームも単離され、線維芽細胞に添加することで、ＭＭＰ−１の発現が上昇すること（非特許文献１）、骨髄由来樹状細胞に添加することで、ＩＬ−６、ＩＬ−１０、ＩＬ−１２の産生が上昇すること（非特許文献２）が報告されている。
しかしながら、ケラチノサイトから放出されるエクソソームがメラノサイトに対して如何なる作用を示すのかは全く知られていない。
On the other hand, exosomes are membrane vesicles surrounded by lipid bilayers, and have been thought to function to release unnecessary intracellular components to the outside. Many cells, including tumor cells, release exosomes, which are important messengers that exchange proteins and lipids between secretory cells (exosome-releasing cells) and their target cells (exosome-receiving cells) It is being done. In recent years, keratinocyte-derived exosomes have also been isolated and added to fibroblasts to increase the expression of MMP-1 (Non-patent Document 1). By adding to bone marrow-derived dendritic cells, IL-6 It has been reported that production of IL-10 and IL-12 is increased (Non-patent Document 2).
However, it is not known at all what the exosomes released from keratinocytes have on melanocytes.
本発明は、皮膚におけるメラニンの過剰産生を抑制でき、皮膚の明色化、色素沈着やシミ・ソバカスの予防又は改善に有用な、メラニン産生抑制剤、美白剤、皮膚色素沈着やシミ・ソバカスの予防又は改善剤、を提供することに関する。 The present invention can suppress the excessive production of melanin in the skin, and is useful for the prevention or improvement of lightening of the skin, pigmentation and stains and freckles, melanin production inhibitor, whitening agent, skin pigmentation and stains and freckles It relates to providing a preventive or ameliorating agent.
本発明者は、メラニン制御に関して種々検討したところ、ケラチノサイトから放出されるエクソソームがメラノサイトに受容され、メラノサイトの増殖及びデンドライト形成を顕著に促進し、メラニン産生を促進することを見出した。すなわち、ケラチノサイト由来のエクソソームは、メラノサイトの細胞増殖能及びメラニン産生能をはじめとした細胞活性を正に制御しており、ケラチノサイトから放出されるエクソソームの分泌を抑制することにより、メラニン産生やデンドライトの伸長を抑制できることを見出した。 As a result of various studies on melanin control, the present inventor has found that exosomes released from keratinocytes are received by melanocytes, remarkably promote melanocyte proliferation and dendrite formation, and promote melanin production. In other words, keratinocyte-derived exosomes positively control cell activity including melanocyte cell proliferation ability and melanin production ability, and by suppressing secretion of exosomes released from keratinocytes, melanin production and dendrite It was found that elongation can be suppressed.
すなわち、本発明は、以下の１）〜４）に係るものである。
１）Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質を有効成分とするメラニン産生抑制剤。
２）Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質を有効成分とする美白剤。
３）Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質を有効成分とするシミ若しくはソバカスの予防又は改善剤。
４）Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌促物質を有効成分とする皮膚色素沈着の予防又は改善剤。
That is, the present invention relates to the following 1) to 4).
1) N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide dihydrochloride, N-[(1R ) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-dien-7-yl) amino] ethyl] -decanamide, L- A keratinocyte-derived exosome secretion inhibitor selected from glutathione (reduced form), 3-O-methyl-sphingomyelin and siRNA formed from the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 Melanin production inhibitor as an active ingredient.
2) N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide dihydrochloride, N-[(1R ) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-dien-7-yl) amino] ethyl] -decanamide, L- A keratinocyte-derived exosome secretion inhibitor selected from glutathione (reduced form), 3-O-methyl-sphingomyelin and siRNA formed from the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 Whitening agent as an active ingredient.
3) N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide dihydrochloride, N-[(1R ) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-dien-7-yl) amino] ethyl] -decanamide, L- A keratinocyte-derived exosome secretion inhibitor selected from glutathione (reduced form), 3-O-methyl-sphingomyelin and siRNA formed from the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 An agent for preventing or improving spots or freckles as an active ingredient.
4) N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide dihydrochloride, N-[(1R ) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-dien-7-yl) amino] ethyl] -decanamide, L- A keratinocyte-derived exosome secretagogue selected from glutathione (reduced form), 3-O-methyl-sphingomyelin and siRNA formed from the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 An agent for preventing or improving skin pigmentation as an active ingredient.
本発明によれば、皮膚のメラニン産生やデンドライトの伸長を抑制させることができ、皮膚の明色化、皮膚色素沈着やシミ若しくはソバカスの予防又は改善を図ることができる。 According to the present invention, the production of melanin in the skin and the extension of dendrites can be suppressed, and the skin lightening, skin pigmentation, spots or freckles can be prevented or improved.
本発明において、ケラチノサイト由来エクソソームの分泌抑制物質とは、ケラチノサイトから放出されるエクソソームの分泌を抑制させる物質を意味する。
ここで、「エクソソーム」とは、ケラチノサイトから恒常的に放出されるエクソソームを意味する。当該エクソソームは、直径が３０〜１００ｎｍで、ｃｕｐ形状を有し、Ｈｅａｔ ｓｈｏｃｋ ｐｒｏｔｅｉｎ ７０（ＨＳＰ７０）、β−Ａｃｔｉｎ、テトラスパニン（ＣＤ９、ＣＤ６３）等のタンパク質を含むという特徴を有することが報告されているが、本発明においてはこれに限定されるものではない。
「分泌抑制」とは、ケラチノサイトからのエクソソームの分泌能を低減化し、ケラチノサイト外へのエクソソームの放出量を減少させることを意味する。
「物質」としては、その種類は特に限定されず、天然物でも合成物でもよく、また単一物質であっても組成物若しくは混合物であってもよい。
In the present invention, the keratinocyte-derived exosome secretion inhibitor means a substance that suppresses the secretion of exosomes released from keratinocytes.
Here, “exosome” means an exosome that is constantly released from keratinocytes. The exosome is reported to have a characteristic that it has a cup shape with a diameter of 30 to 100 nm, and includes proteins such as Heat shock protein 70 (HSP70), β-Actin, tetraspanin (CD9, CD63), and the like. However, the present invention is not limited to this.
“Secrelation inhibition” means that the ability of exosomes to be secreted from keratinocytes is reduced, and the amount of exosomes released outside keratinocytes is reduced.
The type of “substance” is not particularly limited, and may be a natural product or a synthetic product, and may be a single substance, a composition or a mixture.
当該ケラチノサイト由来エクソソームの分泌抑制物質は、以下に示すａ）〜ｃ）の工程によって探索し、取得することができる。
ａ）ケラチノサイトに被験物質を接触させ培養する工程
ｂ）培養細胞からエクソソーム画分を単離し、分泌レベルを測定する工程
ｃ）エクソソームの分泌レベルを低下又は減少させる被験物質を選択する工程
The keratinocyte-derived exosome secretion-inhibiting substance can be searched and obtained by the following steps a) to c).
a) a step of bringing a test substance into contact with keratinocytes and culturing b) a step of isolating an exosome fraction from cultured cells and measuring a secretion level c) a step of selecting a test substance that reduces or decreases the secretion level of exosome
ここで、「ケラチノサイト」としては、自己増殖性を有する正常な表皮角化細胞であれば使用可能であり、ヒト、マウス、ラット、ブタ等の哺乳動物由来の細胞を使用することができるが、ヒトの細胞を用いるのが好ましい。当該ケラチノサイトを用いる場合には、動物よりケラチノサイトを採取し、常法に従って処理して用いることができるが、樹立細胞株として市販されているもの（例えば、ヒト表皮角化細胞株であるHaCaT細胞など）を購入して利用することもできる。ヒトの細胞としては、例えば正常ヒトケラチノサイト（ＮＨＥＫ：Normal Human Epidermal Keratinocytes）が好適に挙げられる。 Here, as the “keratinocyte”, any normal epidermal keratinocytes having self-proliferating properties can be used, and cells derived from mammals such as humans, mice, rats, and pigs can be used. It is preferred to use human cells. When the keratinocytes are used, keratinocytes are collected from animals and can be used after being treated according to a conventional method. However, commercially available as established cell lines (for example, HaCaT cells which are human epidermal keratinocyte cell lines, etc. ) Can be purchased and used. Suitable examples of human cells include normal human keratinocytes (NHEK).
当該細胞と被験物質との接触は、当該細胞が成育可能な条件で培養しながら行われる。例えば、増殖用添加剤（Ｈｕｍｅｄｉａ−ＫＧ）を含むＥｐｉｌｉｆｅ培地（Life Technologies製）、上記、増殖用添加剤のうちｈＥＧＦを含まないＥｐｉｌｉｆｅ培地（Life Technologies製）やCnT-Prime培地（CELLnTEC製）の他、適宜、抗生物質、血清、増殖因子等を添加した培地等の市販の培地中で培養できる。培養は、通常３０℃〜４０℃、１〜１０ｖｏｌ％二酸化炭素存在下で実施すればよく、３７℃、５ｖｏｌ％二酸化炭素存在下で実施するのが好ましい。 The contact between the cell and the test substance is performed while culturing the cell under conditions that allow the cell to grow. For example, an Epilife medium containing Life Additive (Humdia-KG) (Life Technologies), an Epilife medium containing no HEGF (Life Technologies) or a CnT-Prime medium (CELLnTEC) In addition, it can be cultured in a commercially available medium such as a medium supplemented with antibiotics, serum, growth factors and the like as appropriate. The culture is usually carried out in the presence of 30 ° C. to 40 ° C. and 1 to 10 vol% carbon dioxide, and is preferably carried out in the presence of 37 ° C. and 5 vol% carbon dioxide.
また、被験物質と接触させる際のケラチノサイトの細胞数は、例えば６ｗｅｌｌプレートを用いる場合、通常約１０４〜約１０６個／ｗｅｌｌであればよく、５×１０４〜５×１０５個／ｗｅｌｌが好ましい。 Moreover, the number of keratinocyte cells when contacting with the test substance may be usually about 10 4 to about 10 6 cells / well when using a 6- well plate, for example, 5 × 10 4 to 5 × 10 5 cells / well. Is preferred.
エクソソームの単離は、培養上清を回収した後、超遠心機を用いて、異なる速度で段階的に遠心処理することにより行うことができる(Thery C et al. (2006) Curr Protoc Cell Biol., 3.22.1-3.22.29)。具体的には、培養上清を回収し、300gで10分間、2,000gで20分間、10,000gで30分間と段階的に遠心分離することにより、余分な細胞(破片)を除去した培養上清に対し、100,000gで70分間の遠心分離を行った後で上清を除去し、Phosphate Buffered Saline (PBS)にて一度洗浄し、さらに、100,000gで70分間遠心分離した後に完全に上清を除去することにより行うことができる。また、超遠心機を用いずに、エクソソーム膜に曝露されるタンパク質（CD9、CD63、そして、CD81など）に対する抗体でコートされたビーズを用いて、エクソソームを直接単離する免疫吸着法（抗体結合法）を用いることもできる(ref. Wubbolts R et al. (2003) J Biol Chem., 278: 10963-10972)。その他、市販のキット試薬（例えばExosome Precipitation Solution, ExoQuick-TC（System Biosciences社、#EXOTC10A-1 or EXOTC50A-1）やmiRCURY Exosome Isolation Kit (EXIQON社、#300102)、Total Exosome Isolation Reagent
(invitrogen社、#4478359)等）を用いることでもよい。
Isolation of exosomes can be performed by collecting the culture supernatant and then performing stepwise centrifugation at different speeds using an ultracentrifuge (Thery C et al. (2006) Curr Protoc Cell Biol. , 3.22.1-3.22.29). Specifically, the culture supernatant was collected and centrifuged at 300 g for 10 minutes, 2,000 g for 20 minutes, and 10,000 g for 30 minutes to remove excess cells (debris). On the other hand, after centrifugation at 100,000g for 70 minutes, the supernatant was removed, washed once with Phosphate Buffered Saline (PBS), and further centrifuged at 100,000g for 70 minutes to completely remove the supernatant. This can be done by removing. In addition, an immunoadsorption method (antibody binding) that directly isolates exosomes using beads coated with antibodies against proteins (CD9, CD63, and CD81) exposed to the exosome membrane without using an ultracentrifuge (Ref. Wubbolts R et al. (2003) J Biol Chem., 278: 10963-10972). Other commercially available kit reagents such as Exosome Precipitation Solution, ExoQuick-TC (System Biosciences, # EXOTC10A-1 or EXOTC50A-1), miRCURY Exosome Isolation Kit (EXIQON, # 300102), Total Exosome Isolation Reagent
(Invitrogen, # 4478359) may be used.
エクソソームの分泌レベルの低下又は減少は、例えば、被験物質を接触させる細胞群と接触させない群（対照細胞）を用意し、エクソソームの分泌レベルを測定し、両者間で比較することが挙げられる。なお、対照細胞としては、被験物質を接触させない代わりに、対照物質を接触させたものを用いてもよい。
そして、被験物質を添加したエクソソームの分泌レベルが被験物質を添加しない対照細胞でのレベルと比較して低下又は減少する物質をケラチノサイト由来エクソソーム分泌抑制物質として選択する。
The decrease or decrease in the exosome secretion level includes, for example, preparing a group (control cell) that is not brought into contact with a test substance contacted group, measuring the exosome secretion level, and comparing the two. In addition, as a control cell, you may use what contacted the control substance instead of making a test substance contact.
Then, a substance whose exosome secretion level to which the test substance is added is reduced or decreased as compared with the level in the control cell to which the test substance is not added is selected as a keratinocyte-derived exosome secretion inhibitory substance.
エクソソームの分泌レベルの測定は、例えば、エクソソーム画分の総タンパク質量の測定、エクソソーム中に含まれるマーカータンパク質（CD9、CD63、CD81、HSP70、Alix、Tsg101、GM1ガングリオシドなど）の発現量の測定、エクソソームの粒径の分布と濃度の測定、エクソソーム数の測定、エクソソーム中に含まれるRNA（mRNA、small RNA、miRNAなど）の発現量の測定等によって行うことができる。好適には、48〜72時間の間に培養上清中に放出されたエクソソーム画分のタンパク質定量を行い、それを細胞数で除することにより、単位時間における1細胞あたりのエクソソーム放出量を算出することが挙げられる。
各種測定は、当該分野で通常使用される任意の解析方法を用いればよく、遺伝子発現解析には、例えば、ドットブロット法、ノーザンブロット法、ＲＮａｓｅプロテクションアッセイ法、ルシフェラーゼ等によるレポーターアッセイ、ＲＴ−ＰＣＲ法、ＤＮＡマイクロアレイ等を、タンパク質発現解析には、ウェスタンブロッティング法、免疫染色法、ＥＬＩＳＡ、バインディングアッセイ等を用いることができる。また、市販のキット（例えばCD63 ExoELISA Kit（System Biosciences社、#EXOEL-CD63A-1）等）やナノ粒子解析装置（NanoSight LM10（NanoSight社））を用いることもできる。
Measurement of exosome secretion level includes, for example, measurement of total protein amount of exosome fraction, measurement of expression level of marker protein (CD9, CD63, CD81, HSP70, Alix, Tsg101, GM1 ganglioside, etc.) contained in exosome, It can be performed by measuring the distribution and concentration of exosome particle size, measuring the number of exosomes, measuring the expression level of RNA (mRNA, small RNA, miRNA, etc.) contained in the exosome. Preferably, the amount of exosome released per cell per unit time is calculated by performing protein quantification of the exosome fraction released into the culture supernatant during 48 to 72 hours and dividing it by the number of cells. To do.
For the various measurements, any analysis method usually used in the field may be used. For gene expression analysis, for example, dot blot method, Northern blot method, RNase protection assay method, reporter assay by luciferase, RT-PCR, etc. Western blotting method, immunostaining method, ELISA, binding assay, etc. can be used for protein expression analysis of the method, DNA microarray and the like. Commercially available kits (for example, CD63 ExoELISA Kit (System Biosciences, # EXOEL-CD63A-1), etc.) and nanoparticle analyzers (NanoSight LM10 (NanoSight)) can also be used.
ケラチノサイト由来エクソソームの分泌抑制物質としては、例えば、神経細胞由来エクソソームの放出抑制物質として報告（国際特許公開第２０１３／０５４５３４号、Trajkovic K et al., Science (2008)319:1244-1247）されている、Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩；以下「ＧＷ４８６９」とも称する）、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド（Ｎ−ＳＭａｓｅ Ｓｐｉｒｏｅｐｏｘｉｄｅ Ｉｎｈｉｂｉｔｏｒ）、Ｌ−グルタチオン（還元型）（γ−Ｌ−グルタミル−Ｌ−システイニル−グリシン）、３−Ｏ−メチル−スフィンゴミエリンの他、センス配列として5′-AAUCGAUGUAGAUCUUGAUCUGAGG-3′（配列番号１）、アンチセンス配列として5′-CCUCAGAUCAAGAUCUACAUCGAUU-3′（配列番号２）から形成される中性スフィンゴミエリナーゼ２（Ｎ−ＳＭａｓｅ２）の発現を抑制するｓｉＲＮＡ等が挙げられる。 As a keratinocyte-derived exosome secretion inhibitor, for example, it has been reported as a neuronal cell-derived exosome release inhibitor (International Patent Publication No. 2013/045434, Trajkovic K et al., Science (2008) 319: 1244-1247). N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide dihydrochloride; hereinafter referred to as “GW4869” N-[(1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-dien-7-yl) amino ] Ethyl] -decanamide (N-SMase Spiroepoxide Inhibitor), L-glutathione (reduced form) (γ-L-glutamyl-L-cysteinyl-glyce Shin), 3-O-methyl-sphingomyelin, 5'-AAUCGAUGUAGAUCUUGAUCUGAGG-3 '(SEQ ID NO: 1) as a sense sequence, and 5'-CCUCAGAUCAAGAUCUACAUCGAUU-3' (SEQ ID NO: 2) as an antisense sequence Examples include siRNA that suppresses the expression of neutral sphingomyelinase 2 (N-SMase2).
ＧＷ４８６９は公知の方法で化学合成することができ、また市販品（Sigma-Aldrich社製、Cayman Chemical社製、他）を入手して用いることもできる。また、Ｎ−ＳＭａｓｅ Ｓｐｉｒｏｅｐｏｘｉｄｅ ＩｎｈｉｂｉｔｏｒはＳａｎｔａＣｒｕｚ社製の市販品、Ｌ−グルタチオン（還元型）はＳｉｇｍａ−Ａｌｄｒｉｃｈ社製、Ｃａｙｍａｎ Ｃｈｅｍｉｃａｌ社製、その他の市販品、３−Ｏ−メチル−スフィンゴミエリンはＥｎｚｏ Ｌｉｆｅ Ｓｃｉｅｎｃｅ社製、Ａｂｃａｍ社製、その他の市販品、Ｎ−ＳＭａｓｅ２のｓｉＲＮＡはＩｎｖｉｔｒｏｇｅｎ社製、その他の市販品を使用することができる。 GW4869 can be chemically synthesized by a known method, or a commercial product (Sigma-Aldrich, Cayman Chemical, etc.) can be obtained and used. N-SMase Spiroepoxide Inhibitor is a commercial product manufactured by Santa Cruz, L-glutathione (reduced form) is manufactured by Sigma-Aldrich, Cayman Chemical, other commercially available products, and 3-O-methyl-sphingomyelin is enzo Lif Science, Abcam, and other commercially available products, and N-SMase2 siRNA may be Invitrogen and other commercially available products.
後記参考例に示すように、ケラチノサイト由来エクソソームにより、メラノサイトの細胞活性（ドーパオキシダーゼ活性、細胞呼吸鎖活性）が上昇し（図３）、メラニン関連タンパク質をコードする遺伝子（Microphthalmia-associated transcription factor（ＭＩＴＦ）、Tyrosinase (ＴＹＲ）、Tyrosinase related protein 1 (ＴＹＲＰ１）、Dopachrome tautomerase (ＤＣＴ)／Tyrosinase related protein 2 (ＴＹＲＰ２））の発現が上昇し（図４）、メラノサイトの細胞増殖及び形態変化が促進し（細胞数の増加、デンドライトの伸長）（図５）、メラニン関連タンパク質（ＭＩＴＦ、Tyrosinase、ＴＲＰ１、ＴＲＰ２）の発現が上昇し（図６）、さらに、メラニン産生が促進する（図７）。したがって、ケラチノサイト由来のエクソソームは、メラノサイトの細胞活性を正に制御していると考えられる。
故に、ケラチノサイトからのエクソソームの分泌抑制はメラノサイトにおけるメラニン生成量を減少させ、またデンドライトの伸長を抑制すると云える。実際、後記実施例に示すように、ケラチノサイト由来エクソソームの放出抑制物質によりメラニン生成が抑制される（図８〜１１）。
As shown in a reference example described later, keratinocyte-derived exosomes increase melanocyte cellular activity (dopa oxidase activity, cell respiratory chain activity) (FIG. 3), and a gene encoding a melanin-related protein (Microphthalmia-associated transcription factor (MITF)). ), Tyrosinase (TYR), Tyrosinase related protein 1 (TYRP1), Dopachrome tautomerase (DCT) / Tyrosinase related protein 2 (TYRP2)) are increased (FIG. 4), and cell proliferation and morphological changes of melanocytes are promoted ( Increase in the number of cells, extension of dendrites (FIG. 5), the expression of melanin-related proteins (MITF, Tyrosinase, TRP1, TRP2) are increased (FIG. 6), and melanin production is further promoted (FIG. 7). Therefore, keratinocyte-derived exosomes are thought to positively control the cellular activity of melanocytes.
Therefore, suppression of exosome secretion from keratinocytes can reduce melanin production in melanocytes and suppress dendrite elongation. In fact, as shown in the Examples below, melanin production is suppressed by a substance that suppresses the release of keratinocyte-derived exosomes (FIGS. 8 to 11).
したがって、ケラチノサイト由来エクソソームの分泌抑制物質は、メラニン産生抑制剤、美白剤、シミ若しくはソバカスの予防又は改善剤、あるいは皮膚色素沈着の予防又は改善剤（「メラニン産生抑制剤等」と称する）となり得、また、メラニン産生抑制剤、美白剤、シミ若しくはソバカスの予防又は改善、皮膚色素沈着の予防又は改善剤を製造するために使用することができる。すなわち、ケラチノサイト由来エクソソームの分泌抑制物質は、細胞のメラニン産生抑制のため、美白のため、シミ若しくはソバカスの予防又は改善のため、あるいは皮膚色素沈着の予防又は改善のために使用することができる。ここで、ヒトに対する使用は、治療的使用であっても非治療的使用であってもよい。「非治療的」とは、医療行為を含まない概念、すなわち人間を手術、治療又は診断する方法を含まない概念、より具体的には医師又は医師の指示を受けた者が人間に対して手術、治療又は診断を実施する方法を含まない概念である。
また、本発明において、「美白」とは、皮膚が明色化して白くなることを意味し、また、日焼けなどによる黒色化した皮膚が白くなること、さらには、皮膚の黒色化が防止されること、シミやソバカスが薄く目立たなくなること、シミやソバカスの生成が抑制されることを包含する。
「皮膚色素沈着」とは、皮膚に一過的又は慢性的にメラニンなどの色素が沈着または停滞して色素斑が形成された状態を意味する。
Therefore, the keratinocyte-derived exosome secretion inhibitor can be a melanin production inhibitor, whitening agent, spot or buckwheat prevention or improvement agent, or skin pigmentation prevention or improvement agent (referred to as “melanin production inhibitor etc.”). Further, it can be used for producing a melanin production inhibitor, a whitening agent, a spot or buckwheat prevention or improvement, and a skin pigmentation prevention or improvement agent. That is, the keratinocyte-derived exosome secretion inhibitor can be used for inhibiting melanin production in cells, for whitening, for preventing or improving spots or freckles, or for preventing or improving skin pigmentation. Here, the use for human may be therapeutic use or non-therapeutic use. “Non-therapeutic” means a concept that does not include medical practice, that is, a concept that does not include a method for surgery, treatment, or diagnosis of a human, more specifically, a doctor or a person who has received instructions from a doctor operates on a human. It is a concept that does not include a method of performing treatment or diagnosis.
In the present invention, “whitening” means that the skin is lightened and whitened, blackened skin due to sunburn or the like becomes white, and further, blackening of the skin is prevented. This includes that the spots and freckles are thin and inconspicuous, and that the generation of spots and freckles is suppressed.
The “skin pigmentation” means a state in which pigment spots such as melanin are temporarily or chronically deposited or stagnant on the skin.
当該メラニン産生抑制剤等は、それ自体、細胞のメラニン産生抑制、美白、シミ若しくはソバカスの予防又は改善、あるいは皮膚色素沈着の予防又は改善のための、化粧品、医薬品部外品、医薬品であってもよく、又は当該化粧品、医薬部外品、医薬品等に配合して使用される素材又は製剤であってもよい。 The melanin production inhibitor itself is a cosmetic, quasi-drug, or pharmaceutical product for inhibiting melanin production of cells, preventing or improving whitening, spots or freckles, or preventing or improving skin pigmentation. Alternatively, it may be a material or a preparation used by blending with the cosmetic, quasi-drug, or pharmaceutical.
本発明のケラチノサイト由来エクソソームの分泌抑制物質を含有する化粧品、医薬部外品又は医薬品は、好適には皮膚外用剤の形態で、具体的には、軟膏、乳化化粧料、クリーム、乳液、ローション、ジェル、エアゾール等の種々の形態で用いることができる。
斯かる製剤は、それぞれ一般的な製造法により、直接又は製剤上許容し得る担体、例えば、各種油剤、界面活性剤、ゲル化剤、防腐剤、酸化防止剤、溶剤、アルコール、水、キレート剤、増粘剤、紫外線吸収剤、乳化安定剤、ｐＨ調整剤、色素、香料等とともに混合、分散した後、所望の形態に加工することによって得ることができる。また、これらの化粧品、医薬部外品又は医薬品等には、それぞれの製剤に応じて、適宜、植物抽出物、殺菌剤、保湿剤、抗炎症剤、抗菌剤、清涼剤、抗脂漏剤等を本発明の効果を妨害しない範囲で適宜配合することができる。
The cosmetic, quasi-drug or pharmaceutical containing the keratinocyte-derived exosome secretion-suppressing substance of the present invention is preferably in the form of an external preparation for skin, specifically, ointment, emulsified cosmetic, cream, milky lotion, lotion, It can be used in various forms such as gel and aerosol.
Such preparations are prepared according to general production methods, directly or pharmaceutically acceptable carriers such as various oils, surfactants, gelling agents, preservatives, antioxidants, solvents, alcohols, water, chelating agents. It can be obtained by mixing and dispersing together with a thickener, an ultraviolet absorber, an emulsion stabilizer, a pH adjuster, a pigment, a fragrance, and the like, and then processing into a desired form. In addition, for these cosmetics, quasi drugs or pharmaceuticals, etc., plant extracts, bactericides, moisturizers, anti-inflammatory agents, antibacterial agents, cooling agents, antiseborrheic agents, etc. Can be appropriately blended within a range not impeding the effects of the present invention.
当該化粧品、医薬部外品又は医薬品中の本発明のケラチノサイト由来エクソソームの分泌抑制物質の含有量は、一般的に０．００００１質量％以上、好ましくは０．０００１質量％以上であり、そして１質量％以下、好ましくは０.１質量％以下である。また、０．００００１〜１質量％とするのが好ましく、０．０００１〜０.１質量％とするのがより好ましい。 The content of the keratinocyte-derived exosome secretion-inhibiting substance of the present invention in the cosmetic, quasi-drug or pharmaceutical is generally 0.00001% by mass or more, preferably 0.0001% by mass or more, and 1% by mass. % Or less, preferably 0.1% by mass or less. Moreover, it is preferable to set it as 0.00001-1 mass%, and it is more preferable to set it as 0.0001-0.1 mass%.
上記化粧品、医薬部外品又は医薬品の投与量は、効果が得られる量であれば特に限定されず、対象者の状態、体重、性別、年齢又はその他の要因に従って変動し得るが、成人（６０ｋｇ）１人当たり１日、ケラチノサイト由来エクソソームの分泌抑制物質として、例えば、好ましくは０．００１ｍｇ以上であり、そして１０００ｍｇ以下、好ましくは１００ｍｇ以下である。また、０．００１〜１０００ｍｇとするのが好ましく、更に０．００１〜１００ｍｇとするのが好ましい。また、当該製剤は、任意の摂取・投与計画に従って摂取・投与され得るが、１日１回〜数回に分け、数週間〜数カ月間継続して投与することが好ましい。このうち、１日３回に分け、６週間以上継続して投与することがより好ましい。
また、上記化粧品、医薬品又は医薬部外品の適用対象者としては、それを必要としていれば特に限定されないが、美白を所望するヒト、シミ若しくはソバカスの予防又は改善を所望するヒト、あるいは皮膚色素沈着の予防又は改善を所望するヒトが挙げられる。
The dosage of the above cosmetics, quasi drugs or pharmaceuticals is not particularly limited as long as the effect is obtained, and may vary according to the condition, weight, sex, age or other factors of the subject. ) As a keratinocyte-derived exosome secretion inhibitor, for example, it is preferably 0.001 mg or more and 1000 mg or less, preferably 100 mg or less per day per person. Moreover, it is preferable to set it as 0.001-1000 mg, and also it is preferable to set it as 0.001-100 mg. The preparation can be ingested / administered according to any ingestion / administration plan, but is preferably divided into once to several times a day and continuously administered for several weeks to several months. Among these, it is more preferable to divide into 3 times a day and to administer continuously for 6 weeks or more.
In addition, the application target of the cosmetics, pharmaceuticals or quasi drugs is not particularly limited as long as it is necessary, but humans who desire whitening, humans who desire prevention or improvement of spots or freckles, or skin pigments Examples include humans who wish to prevent or improve deposition.
上述した実施形態に関し、本発明においては以下の態様が開示される。
＜１＞Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質を有効成分とするメラニン産生抑制剤。
＜２＞Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質を有効成分とする美白剤。
＜３＞Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質を有効成分とするシミ若しくはソバカスの予防又は治療剤。
＜４＞Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質を有効成分とする皮膚色素沈着の予防又は改善剤。
＜５＞ケラチノサイト由来エクソソームの分泌抑制物質が、Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩である、＜１＞のメラニン産生抑制剤、＜２＞の美白剤、＜３＞のシミ若しくはソバカスの予防又は治療剤、又は＜４＞の皮膚色素沈着の予防又は改善剤。
With respect to the above-described embodiment, the following aspects are disclosed in the present invention.
<1> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide dihydrochloride, N-[( 1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-dien-7-yl) amino] ethyl] -decanamide, L -Keratinocyte-derived exosome secretion inhibitor selected from glutathione (reduced form), 3-O-methyl-sphingomyelin and siRNA formed from the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 Melanin production inhibitor comprising
<2> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide dihydrochloride, N-[( 1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-dien-7-yl) amino] ethyl] -decanamide, L -Keratinocyte-derived exosome secretion inhibitor selected from glutathione (reduced form), 3-O-methyl-sphingomyelin and siRNA formed from the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 Whitening agent containing as an active ingredient.
<3> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide dihydrochloride, N-[( 1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-dien-7-yl) amino] ethyl] -decanamide, L -Keratinocyte-derived exosome secretion inhibitor selected from glutathione (reduced form), 3-O-methyl-sphingomyelin and siRNA formed from the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 A preventive or therapeutic agent for stains or buckwheat, comprising as an active ingredient.
<4> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide dihydrochloride, N-[( 1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-dien-7-yl) amino] ethyl] -decanamide, L -Keratinocyte-derived exosome secretion inhibitor selected from glutathione (reduced form), 3-O-methyl-sphingomyelin and siRNA formed from the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 A preventive or ameliorating agent for skin pigmentation comprising
<5> The keratinocyte-derived exosome secretion inhibitor is N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis- <1> a melanin production inhibitor, <2> a whitening agent, <3> a stain or freckles prevention or treatment agent, or <4> a skin pigmentation prevention or improvement agent, which is acrylamide dihydrochloride.
＜６＞メラニン産生抑制剤を製造するための、Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質の使用。
＜７＞美白剤を製造するための、Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質の使用。
＜８＞シミ若しくはソバカスの予防又は改善剤を製造するための、Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質の使用。
＜９＞皮膚色素沈着の予防又は改善剤を製造するための、Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質の使用。
＜１０＞メラニン産生を抑制するための、Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質の使用。
＜１１＞美白のための、Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質の使用。
＜１２＞シミ若しくはソバカスを予防又は改善するための、Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質の使用。
＜１３＞皮膚色素沈着を予防又は改善するための、Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質の使用。
＜１４＞Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質を投与又は摂取する、メラニン産生抑制方法。
＜１５＞Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質を投与又は摂取する、美白方法。
＜１６＞Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質を投与又は摂取する、シミ若しくはソバカスの予防又は改善方法。
＜１７＞Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩、Ｎ−［（１Ｒ）−１−（ヒドロキシメチル）−２−オキソ−２−［（４−オキソ−１−オキサスピロ［２．５］オクタ−５，７−ジエン−７−イル）アミノ］エチル］−デカナミド、Ｌ−グルタチオン（還元型）、３−Ｏ−メチル−スフィンゴミエリン及び配列番号１に示されるセンス配列と配列番号２に示されるアンチセンス配列とから形成されるｓｉＲＮＡから選ばれるケラチノサイト由来エクソソームの分泌抑制物質を投与又は摂取する、皮膚色素沈着の予防又は改善方法。
＜１８＞＜６＞〜＜１７＞において、ケラチノサイト由来エクソソームの分泌抑制物質は、好ましくは、Ｎ，Ｎ’−ビス［４−（４，５−ジヒドロ−１Ｈ−イミダゾール−２−イル）フェニル］−３，３’−ｐ−フェニレン−ビス−アクリルアミド ２塩酸塩である。
＜１９＞＜１０＞〜＜１３＞において、使用は非治療的使用である。
＜２０＞＜１４＞〜＜１７＞において、方法は非治療的方法である。
＜２１＞＜１＞〜＜１８＞において、ケラチノサイト由来エクソソームの分泌抑制物質は製剤中に含有されるものであり、当該製剤中の前記ケラチノサイト由来エクソソームの分泌抑制物質の含有量は、好ましくは０．０００１質量％以上であり、好ましくは０.１質量％以下である。また、好ましくは０．００００１〜１質量％、より好ましくは０．０００１〜０.１質量％である。
<6> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis for producing a melanin production inhibitor Acrylamide dihydrochloride, N-[(1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-diene-7- Yl) amino] ethyl] -decanamide, L-glutathione (reduced form), 3-O-methyl-sphingomyelin and siRNA formed from the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 Use of a keratinocyte-derived exosome secretion inhibitor selected from
<7> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide for producing a whitening agent Dihydrochloride, N-[(1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-dien-7-yl) Amino] ethyl] -decanamide, L-glutathione (reduced form), 3-O-methyl-sphingomyelin and siRNA formed from the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 Use of a keratinocyte-derived exosome secretion inhibitor.
<8> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p for producing an agent for preventing or improving spots or freckles -Phenylene-bis-acrylamide dihydrochloride, N-[(1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7- Diene-7-yl) amino] ethyl] -decanamide, L-glutathione (reduced), 3-O-methyl-sphingomyelin and the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2. Use of a keratinocyte-derived exosome secretion inhibitor selected from siRNA formed.
<9> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p for producing an agent for preventing or improving skin pigmentation -Phenylene-bis-acrylamide dihydrochloride, N-[(1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7- Diene-7-yl) amino] ethyl] -decanamide, L-glutathione (reduced), 3-O-methyl-sphingomyelin and the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2. Use of a keratinocyte-derived exosome secretion inhibitor selected from siRNA formed.
<10> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide for suppressing melanin production Dihydrochloride, N-[(1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-dien-7-yl) Amino] ethyl] -decanamide, L-glutathione (reduced form), 3-O-methyl-sphingomyelin and siRNA formed from the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 Use of a keratinocyte-derived exosome secretion inhibitor.
<11> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide dihydrochloride for whitening N-[(1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] oct-5,7-dien-7-yl) amino] ethyl ] -Decanamide, L-glutathione (reduced form), 3-O-methyl-sphingomyelin and keratinocyte selected from siRNA formed from sense sequence shown in SEQ ID NO: 1 and antisense sequence shown in SEQ ID NO: 2 Use of exosome secretion inhibitor.
<12> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene- for preventing or improving spots or freckles Bis-acrylamide dihydrochloride, N-[(1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-diene-7 -Yl) amino] ethyl] -decanamide, L-glutathione (reduced form), 3-O-methyl-sphingomyelin and the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 Use of a keratinocyte-derived exosome secretion inhibitor selected from siRNA.
<13> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene- for preventing or improving skin pigmentation Bis-acrylamide dihydrochloride, N-[(1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-diene-7 -Yl) amino] ethyl] -decanamide, L-glutathione (reduced form), 3-O-methyl-sphingomyelin and the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 Use of a keratinocyte-derived exosome secretion inhibitor selected from siRNA.
<14> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide dihydrochloride, N-[( 1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-dien-7-yl) amino] ethyl] -decanamide, L -Keratinocyte-derived exosome secretion inhibitor selected from glutathione (reduced form), 3-O-methyl-sphingomyelin and siRNA formed from the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 A method for inhibiting melanin production, comprising administering or ingesting
<15> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide dihydrochloride, N-[( 1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-dien-7-yl) amino] ethyl] -decanamide, L -Keratinocyte-derived exosome secretion inhibitor selected from glutathione (reduced form), 3-O-methyl-sphingomyelin and siRNA formed from the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 Whitening method of administering or ingesting.
<16> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide dihydrochloride, N-[( 1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-dien-7-yl) amino] ethyl] -decanamide, L -Keratinocyte-derived exosome secretion inhibitor selected from glutathione (reduced form), 3-O-methyl-sphingomyelin and siRNA formed from the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 To prevent or ameliorate spots or freckles.
<17> N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -3,3′-p-phenylene-bis-acrylamide dihydrochloride, N-[( 1R) -1- (hydroxymethyl) -2-oxo-2-[(4-oxo-1-oxaspiro [2.5] octa-5,7-dien-7-yl) amino] ethyl] -decanamide, L -Keratinocyte-derived exosome secretion inhibitor selected from glutathione (reduced form), 3-O-methyl-sphingomyelin and siRNA formed from the sense sequence shown in SEQ ID NO: 1 and the antisense sequence shown in SEQ ID NO: 2 A method for preventing or ameliorating skin pigmentation.
<18> In <6> to <17>, the keratinocyte-derived exosome secretion inhibitor is preferably N, N′-bis [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl]. -3,3'-p-phenylene-bis-acrylamide dihydrochloride.
<19> In <10> to <13>, the use is a non-therapeutic use.
<20> In <14> to <17>, the method is a non-therapeutic method.
<21> In <1> to <18>, the keratinocyte-derived exosome secretion inhibitor is contained in the preparation, and the content of the keratinocyte-derived exosome secretion inhibitor in the preparation is preferably 0. It is 0.0001 mass% or more, preferably 0.1 mass% or less. Moreover, Preferably it is 0.00001-1 mass%, More preferably, it is 0.0001-0.1 mass%.
以下、実施例を示し、本発明をより具体的に説明する。
参考例1：ケラチノサイト由来エクソソームの単離とその特徴付け
（１）細胞培養
正常ヒト新生児包皮由来表皮角化細胞(凍結NHEK (F) Lightly; ケラチノサイト)、表皮角化細胞用増殖培地(Epilife)はLife Technologies社より、その培地用増殖添加剤(Humedia-KG)はクラボウ社より購入した。ケラチノサイトは、37℃ 5Vol%CO2の環境下で培養した。
EXAMPLES Hereinafter, an Example is shown and this invention is demonstrated more concretely.
Reference Example 1: Isolation and characterization of keratinocyte-derived exosomes (1) Cell culture Normal human neonatal foreskin-derived epidermal keratinocytes (frozen NHEK (F) Lightly; keratinocytes), epidermal keratinocyte growth medium (Epilife) The media growth additive (Humedia-KG) was purchased from Life Technologies, Inc. from Kurabo Industries. Keratinocytes were cultured in an environment of 37 ° C. and 5 Vol% CO 2 .
（２）ケラチノサイト由来エクソソームの単離
ケラチノサイトを2.5×106cells/flask (25mL/flask)の細胞密度で175cm2 flaskに播種した。この時の培地としては、ヒト上皮細胞成長因子(hEGF; Human Epidermal Growth Factor)以外のHumedia-KG増殖添加剤（インスリン、ハイドロコーチゾン、BPE、ゲンタマイシン/アンフォテリシンB）を含むEpilife培地を使用した。3日間の培養後、培養上清を回収し、300gで10分間、2,000gで20分間、10,000gで30分間と段階的に遠心分離することにより、余分な細胞(破片)を除去した。この操作を終えた後の培養上清に対し、100,000gで70分間の遠心分離を行った後で上清を除去し、Phosphate Buffered Saline (PBS)にて一度洗浄した。さらに、100,000gで70分間遠心分離した後に完全に上清を除去し、沈殿物をPBSにて懸濁した。100 mLの培養上清から遠心分離した場合、最終沈殿物は200 μLのPBSにて懸濁し、これを原液として評価に用いた。また、100,000g遠心後の上清はAmicon(R) Ultra Centrifugal Filters Ultra(R)-3K (Millipore)に供し、4,800rpmで45分間遠心処理を行った。遠心処理後にフィルター上部に残留した液を培養上清濃縮物として回収した。また、細胞非培養の培地に対して同様の処理を施した液を培地濃縮物として回収した。
(2) Isolation of keratinocyte-derived exosomes Keratinocytes were seeded in a 175 cm 2 flask at a cell density of 2.5 × 10 6 cells / flask (25 mL / flask). As the medium at this time, Epilife medium containing Humedia-KG proliferation additives (insulin, hydrocortisone, BPE, gentamicin / amphotericin B) other than human epidermal growth factor (hEGF) was used. After culturing for 3 days, the culture supernatant was collected and centrifuged at 300 g for 10 minutes, 2,000 g for 20 minutes, and 10,000 g for 30 minutes to remove excess cells (debris). The culture supernatant after this operation was centrifuged at 100,000 g for 70 minutes, and then the supernatant was removed and washed once with Phosphate Buffered Saline (PBS). Further, after centrifugation at 100,000 g for 70 minutes, the supernatant was completely removed, and the precipitate was suspended in PBS. When centrifugation was performed from 100 mL of the culture supernatant, the final precipitate was suspended in 200 μL of PBS and used as a stock solution for evaluation. The supernatant after centrifugation at 100,000 g was subjected to Amicon® Ultra Centrifugal Filters Ultra®-3K (Millipore) and centrifuged at 4,800 rpm for 45 minutes. The liquid remaining on the top of the filter after centrifugation was collected as a culture supernatant concentrate. Moreover, the liquid which performed the same process with respect to the culture medium of a cell non-culture was collect | recovered as a culture medium concentrate.
（３）単離したエクソソーム画分の電子顕微鏡観察
単離したエクソソーム画分をPBSもしくはHEPES(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) bufferにて適宜希釈した。その溶液を親水化処理したコロジオン膜貼付メッシュ 400メッシュ(日新EM)に5 μL滴下し、5分間静置した。膜上の水分を吸い取った後、2% Sodium Dodecatungsto(VI) phosphate n-Hydrate (wako)もしくはEMステイナー(日新EM)を10 μL滴下し、1分間もしくは30分間静置することにより、ネガティブ染色を行った。膜上の水分を除いた後、精製水を10 μL滴下した。余分な水分を除いた後、H7650透過型電子顕微鏡(日立)を用いて加速電圧100kVで観察した。その結果、既報と同様に、エクソソームに特徴的なサイズ (直径30-100 nm)と形態 (cup-shaped) を示す小胞を確認した(図1)。
(3) Electron microscope observation of the isolated exosome fraction The isolated exosome fraction was appropriately diluted with PBS or HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) buffer. 5 μL of this solution was dropped onto 400 mesh (Nisshin EM) of a collodion membrane-attached mesh that had been subjected to a hydrophilic treatment, and allowed to stand for 5 minutes. After absorbing moisture on the membrane, add 10 μL of 2% Sodium Dodecatungsto (VI) phosphate n-Hydrate (wako) or EM stainer (Nisshin EM) and leave it for 1 minute or 30 minutes for negative staining. Went. After removing water on the membrane, 10 μL of purified water was added dropwise. After removing excess moisture, observation was performed using an H7650 transmission electron microscope (Hitachi) at an acceleration voltage of 100 kV. As a result, as in the previous report, we confirmed vesicles exhibiting a characteristic size (diameter 30-100 nm) and cup-shaped (Fig. 1).
（４）単離したエクソソーム画分におけるマーカータンパク質の発現確認
単離したエクソソーム画分をResuspension buffer (ambion)にて溶解し、その溶液についてBovine Serum Albumin (BSA)を標準物質としたBCA（ビシンコニン酸）法によりタンパク質定量を行った後、細胞抽出物、培養上清濃縮物及び培地濃縮物と共に、タンパク質量を揃え、定法に従ってSDS-PAGE及びウェスタンブロットに供した。一次抗体は、anti-CD9 (Santacruz, 1:1000)抗体、anti-CD63 (Santacruz, 1:1000)抗体、anti-Calnexin (Cell Signaling, 1:1000)抗体、anti-HSP70 (Cell Signaling, 1:1000)抗体、あるいはanti-β-actin (Sigma-Aldrich, 1:5000)抗体を用いた。二次抗体は、anti-mouse IgG, HRP-Linked F(ab’)2Fragment Sheep (GE Healthcare Life Science)あるいはanti-rabbit IgG HRP-Linked F(ab’)2 Fragment Donkey (GE Healthcare Life Science) を用いた。 その後、ECL plus western blotting detection reagents (GE healthcare bioscience)を用いて発色させ、LAS4000(富士フィルム)を用いて可視化した。その結果、エクソソームに特徴的に発現するマーカーとされるタンパク質群、すなわち、細胞質に存在するHeat shock protein 70、細胞骨格タンパク質であるActin、また、テトラスパニン(CD9、CD63)の発現がエクソソーム画分に確認され、さらにエクソソームには含有されないとして知られるCalnexinの発現が認められないことも確認された(図2)。それと同時に、ケラチノサイトの培養上清濃縮物(図2; lane2)には、Hsp70を除くエクソソームマーカータンパク質の発現が認められなかったことから、エクソソームがその濃縮過程で除去されていることを確認した。なお、Hsp70の発現が培養上清濃縮物で認められたことは既報（Chavez-Munoz C. et al., 2008, J.Cell. Biochem. 104:2165-2173）と同様の結果である。
(4) Confirmation of marker protein expression in the isolated exosome fraction The isolated exosome fraction was dissolved in Resuspension buffer (ambion), and the solution was BCA (bicinchoninic acid) using Bovine Serum Albumin (BSA) as a standard substance. After protein quantification by the method, the amount of protein was prepared together with the cell extract, culture supernatant concentrate and medium concentrate, and subjected to SDS-PAGE and Western blotting according to conventional methods. Primary antibodies are anti-CD9 (Santacruz, 1: 1000) antibody, anti-CD63 (Santacruz, 1: 1000) antibody, anti-Calnexin (Cell Signaling, 1: 1000) antibody, anti-HSP70 (Cell Signaling, 1: 1000). 1000) antibody or anti-β-actin (Sigma-Aldrich, 1: 5000) antibody. Secondary antibodies include anti-mouse IgG, HRP-Linked F (ab ') 2 Fragment Sheep (GE Healthcare Life Science) or anti-rabbit IgG HRP-Linked F (ab') 2 Fragment Donkey (GE Healthcare Life Science). Using. Thereafter, the color was developed using ECL plus western blotting detection reagents (GE healthcare bioscience) and visualized using LAS4000 (Fuji Film). As a result, proteins expressed as markers characteristic of exosomes, namely, heat shock protein 70 in the cytoplasm, Actin, a cytoskeletal protein, and tetraspanins (CD9, CD63) are expressed in the exosome fraction. It was also confirmed that the expression of Calnexin, which is known not to be contained in exosomes, was not observed (FIG. 2). At the same time, the keratinocyte culture supernatant concentrate (Fig. 2; lane2) showed no expression of exosome marker proteins except Hsp70, confirming that exosomes were removed during the concentration process. . The expression of Hsp70 was observed in the culture supernatant concentrate, which is the same result as previously reported (Chavez-Munoz C. et al., 2008, J. Cell. Biochem. 104: 2165-2173).
以上のことより、ケラチノサイトの培養上清より単離した画分がエクソソーム画分と呼ぶに値するものと判断し、これを用いて、以降の評価を行った。 From the above, it was judged that the fraction isolated from the culture supernatant of keratinocytes deserves to be called the exosome fraction, and the subsequent evaluation was performed using this.
参考例2：ケラチノサイト由来エクソソームがメラノサイトに及ぼす影響
（１）細胞培養
正常ヒト新生児包皮由来表皮メラニン細胞(凍結NHEM (NB) Darkly; メラノサイト)、表皮メラニン細胞用増殖培地(Medium254)、その培地用増殖添加剤(HMGS)はLife Technologiesより購入した。メラノサイトは、37℃ 5Vol%CO2の環境下で培養した。
Reference Example 2: Effect of keratinocyte-derived exosomes on melanocytes (1) Cell culture Normal human neonatal foreskin-derived epidermal melanocytes (frozen NHEM (NB) Darkly; melanocytes), epidermal melanocyte growth medium (Medium254), proliferation for the medium Additive (HMGS) was purchased from Life Technologies. Melanocytes were cultured in an environment of 37 ° C. and 5 Vol% CO 2 .
（２）メラノサイトに対するケラチノサイト由来エクソソーム画分の処理
メラノサイトを1.0×104 cells/well (100 μL/well)、1.0×105 cells/well (500 μL/well)及び1.5×105 cells/well (1.5 mL/well)の細胞密度で96-well plate、12-well plate及び6-well plateにそれぞれ播種した。この時の試験用培地としては、Medium254 (増殖添加剤（HMGS）のうち、Fetal Bovine Serum (FBS)、Human Fibroblast growth factor-basic (hFGF-B)ハイドロコーチゾン、インスリン、トランスフェリン、ヘパリン含有、phorbol 12-myristate 13-acetate (PMA)及びbovine pituitary extract (BPE)不含）を用いた。2日後、PBSにて懸濁したエクソソーム画分を添加した後、さらに、96-well plateにおいては5日間、12-well plateにおいては3日間もしくは4日間培養し、それぞれドーパオキシダーゼ活性の計測及び定量的RT-PCR解析に用いた。6-well plateにおいては5日間培養した後に、細胞数の計測及び形態観察、ウェスタンブロッティング解析、さらに、細胞内メラニン定量に用いた。
(2) Treatment of keratinocyte-derived exosome fraction on melanocytes 1.0 × 10 4 cells / well (100 μL / well), 1.0 × 10 5 cells / well (500 μL / well) and 1.5 × 10 5 cells / well ( The cells were seeded in 96-well plate, 12-well plate and 6-well plate at a cell density of 1.5 mL / well, respectively. The medium for the test at this time was Medium 254 (of the growth additive (HMGS), Fetal Bovine Serum (FBS), Human Fibroblast growth factor-basic (hFGF-B) hydrocortisone, insulin, transferrin, heparin contained, phorbol 12 -myristate 13-acetate (PMA) and bovine pituitary extract (BPE) free) were used. Two days later, after adding the exosome fraction suspended in PBS, the cells were further cultured for 5 days in a 96-well plate and 3 days or 4 days in a 12-well plate. Measurement and quantification of dopa oxidase activity, respectively. Used for quantitative RT-PCR analysis. In 6-well plates, after culturing for 5 days, the cells were used for counting and morphological observation, Western blotting analysis, and intracellular melanin quantification.
（３）ケラチノサイト由来エクソソームがメラノサイトのドーパオキシダーゼ活性に及ぼす影響
96-well plateでの培養終了後、培地を全量置換し(100 μL/well)、アラマーブルー(Bio-Rad AbD Serotec Limited)試薬を10 μL/wellになるように添加した。37℃、5Vol%CO2の条件下で1時間インキュベートした後、培地の蛍光強度 (Ex544nm/Em590nm)を測定することで細胞呼吸鎖(増殖)活性を評価した。その後、細胞の培養プレートをPBSで3回洗浄して、抽出Buffer (0.1 M Tris-HCL (pH:7.2）、1% NP-40、0.01% SDS)を20 μL/well、Assay Buffer (4%ジメチルホルムアミド、100 mM Sodium phosphate-buffered (pH:7.1))を20 μL/well添加した。4℃にて2時間かけて細胞を可溶化し、ドーパオキシダーゼ活性の測定を行ったが、その活性測定は、MBTH法（Winder A. et al., 1991, Eur.J. Biochem. 198:317-326）を基本とした次に示す方法で行った。すなわち、可溶化した細胞溶液の各wellに、上記Assay Bufferを80 μL、20.7 mM MBTH (3-メチル-2-ベンゾチアゾリノン ヒドラゾン)溶液を60 μL、基質として5 mM L-DOPA (L-ジヒドロキシフェニルアラニン)溶液を40 μL加え、37℃にて30〜60分間反応させた後、その吸光度を505 nmの測定波長で測定した。その結果、PBSのみを添加したコントロールと比較して、同画分添加による両活性の有意な上昇を確認した(図3A、B)。
(3) Effects of keratinocyte-derived exosomes on dopa oxidase activity of melanocytes
After completion of the culture in the 96-well plate, the entire medium was replaced (100 μL / well), and Alamar Blue (Bio-Rad AbD Serotec Limited) reagent was added to 10 μL / well. 37 ° C., after 1 hour under the conditions of 5 vol% CO 2, cells were assessed respiratory chain (proliferation) activity by measuring the medium fluorescence intensity (Ex 544nm / Em 590nm). After that, the cell culture plate was washed 3 times with PBS, extracted buffer (0.1 M Tris-HCL (pH: 7.2), 1% NP-40, 0.01% SDS) in 20 μL / well, Assay Buffer (4% Dimethylformamide, 100 mM Sodium phosphate-buffered (pH: 7.1)) was added at 20 μL / well. Cells were solubilized at 4 ° C. for 2 hours, and dopa oxidase activity was measured. The activity was measured by the MBTH method (Winder A. et al., 1991, Eur. J. Biochem. 198: 317). -326) based on the following method. Specifically, in each well of the solubilized cell solution, 80 μL of the above Assay Buffer, 60 μL of 20.7 mM MBTH (3-methyl-2-benzothiazolinone hydrazone) solution, and 5 mM L-DOPA (L- After adding 40 μL of dihydroxyphenylalanine) solution and reacting at 37 ° C. for 30 to 60 minutes, the absorbance was measured at a measurement wavelength of 505 nm. As a result, compared with the control to which only PBS was added, a significant increase in both activities was confirmed by the addition of the same fraction (FIGS. 3A and B).
（４）ケラチノサイト由来エクソソームがメラノサイトのメラニン関連遺伝子の発現量に及ぼす影響
12-well plateでの培養終了後、細胞をPBSで洗浄した後、RNeasy Mini Kit (QIAGEN）を用いて定法に従いtotal RNAを抽出した。その抽出したtotal RNAを鋳型とし、High Capacity RNA to cDNA Kit (Life Technologies)を用いた逆転写反応によりcDNAを合成した。反応には、MH Research社製のPeltier Thermal Cyclerを用いた。続いて合成したcDNA及びTaqMan(R)probeを用いて、定量的PCR法による遺伝子発現解析を行った。各遺伝子に特異的なprobe及びprimerは、Life Technologies社製のTaqMan(R)Gene Expression Assays (P/N 4331182)を使用した。各々の発現量は、内部標準遺伝子であるribosomal protein, large, P0 (RPLP0)の発現量により補正した。反応条件は定法に従い、アプライドバイオシステムズ社製のシークエンスディテクター(ABI PRISM 7500 Real Time PCR System)を用いて行った。その結果、エクソソーム画分を添加して72時間後にMITFの発現上昇を確認し(図4A)、96時間後にはTYR、TYRP1、Dopachrome tautomerase (DCT) /TYRP2の発現上昇を確認した(図4B)。
(4) Effects of keratinocyte-derived exosomes on the expression level of melanocytes-related genes in melanocytes
After culturing in the 12-well plate, the cells were washed with PBS, and total RNA was extracted according to a conventional method using RNeasy Mini Kit (QIAGEN). Using the extracted total RNA as a template, cDNA was synthesized by a reverse transcription reaction using High Capacity RNA to cDNA Kit (Life Technologies). For the reaction, Peltier Thermal Cycler manufactured by MH Research was used. Subsequently, gene expression analysis by quantitative PCR was performed using the synthesized cDNA and TaqMan (R) probe. Probes and primers specific to each gene were TaqMan® Gene Expression Assays (P / N 4331182) manufactured by Life Technologies. Each expression level was corrected by the expression level of ribosomal protein, large, P0 (RPLP0), which is an internal standard gene. Reaction conditions were determined according to a standard method using a sequence detector (ABI PRISM 7500 Real Time PCR System) manufactured by Applied Biosystems. As a result, 72 hours after addition of the exosome fraction, MITF increased expression was confirmed (Fig.4A), and 96 hours later, increased expression of TYR, TYRP1, Dopachrome tautomerase (DCT) / TYRP2 was confirmed (Figure 4B). .
（５）ケラチノサイト由来エクソソームがメラノサイトの細胞増殖能及び形態形成に及ぼす影響
6-well plateでの培養終了後、顕微鏡観察をおこない、画像を記録した。その後、0.25% Trypsin-EDTA 溶液(Life Technologies)処理を施して、細胞接着を剥離した後に回収し、血球計算板を用いて細胞数のカウントを行った。その結果、エクソソーム画分を添加して5日後に、PBSを添加したコントロールに対して、細胞数の有意な増加を確認すると共に(図5A)、デンドライトの顕著な伸長を確認した(図5B)。
(5) Effects of keratinocyte-derived exosomes on cell proliferation ability and morphogenesis of melanocytes
After culturing in the 6-well plate, microscopic observation was performed and images were recorded. Thereafter, the cells were treated with 0.25% Trypsin-EDTA solution (Life Technologies) to remove the cell adhesion, and then collected, and the number of cells was counted using a hemocytometer. As a result, 5 days after adding the exosome fraction, a significant increase in the number of cells was confirmed with respect to the control to which PBS was added (FIG. 5A), and a significant extension of dendrites was confirmed (FIG. 5B). .
（６）ケラチノサイト由来エクソソームがメラノサイトのメラニン関連タンパク質の発現量に及ぼす影響
6-well plateでの培養終了後、細胞をPBSで洗浄し、RIPA buffer (Sigma-Aldrich)を用いて回収してから、超音波処理により細胞を破砕した。その後、15,000rpmで15分間遠心分離し、その上清についてBovine Serum Albumin (BSA)を標準物質としたBCA（ビシンコニン酸）法によりタンパク量を定量した後、各群のタンパク質量を揃え、定法に従ってSDS-PAGE及びウェスタンブロットに供した。一次抗体は、anti-MITF (Santacruz, 1:200)、anti-Tyrosinase related protein (TRP) 1 (Santacruz, 1:1000)、anti-TRP2 (Santacruz, 1:200)、あるいはanti-Tyrosinase (Zymed, 1:1000)を用いた。二次抗体は、anti-mouse IgG, HRP-Linked F(ab’)2 Fragment Sheep (GE Healthcare Life Science)、あるいはanti-goat IgG, HRP-Linked F(ab’)2Fragment Sheep (GE Healthcare Life Science)を用いた。 その後、ECL plus western blotting detection reagents (GE healthcare bioscience)を用いて発色させ、LAS4000 (GE healthcare bioscience)を用いて発現量を可視化した。内部標準としてのβ-actinの発現は、monoclonal antibody specific for β-actin (Sigma-Aldrich, 1:5000)を用いて評価した。上記タンパク質の検出バンドの強度を画像解析により定量した結果、PBSを添加したコントロールに対して、全てのタンパク質が有意に発現上昇していることを確認した(図6)。
(6) Effects of keratinocyte-derived exosomes on the expression level of melanocytes in melanocytes
After completion of the culture in the 6-well plate, the cells were washed with PBS, recovered using RIPA buffer (Sigma-Aldrich), and then disrupted by sonication. Thereafter, the mixture was centrifuged at 15,000 rpm for 15 minutes, and the supernatant was quantified by the BCA (bicinchoninic acid) method using Bovine Serum Albumin (BSA) as a standard substance. SDS-PAGE and Western blot were used. Primary antibodies are anti-MITF (Santacruz, 1: 200), anti-Tyrosinase related protein (TRP) 1 (Santacruz, 1: 1000), anti-TRP2 (Santacruz, 1: 200), or anti-Tyrosinase (Zymed, 1: 1000) was used. Secondary antibodies are anti-mouse IgG, HRP-Linked F (ab ') 2 Fragment Sheep (GE Healthcare Life Science), or anti-goat IgG, HRP-Linked F (ab') 2 Fragment Sheep (GE Healthcare Life Science ) Was used. Thereafter, color was developed using ECL plus western blotting detection reagents (GE healthcare bioscience), and the expression level was visualized using LAS4000 (GE healthcare bioscience). Expression of β-actin as an internal standard was evaluated using monoclonal antibody specific for β-actin (Sigma-Aldrich, 1: 5000). As a result of quantifying the intensity of the detection band of the protein by image analysis, it was confirmed that the expression of all proteins was significantly increased with respect to the control to which PBS was added (FIG. 6).
（７）ケラチノサイト由来エクソソームがメラノサイトのメラニン産生に及ぼす影響
6-well plateでの培養終了後、細胞をPBSで洗浄し、セルスクレーパーを用いてエッペンドルフチューブに細胞を回収した。各エッペンドルフチューブに2M NaOHを150 μL加えた後100℃にて細胞を溶解させ、遠心処理によって得られた上清について405 nmの測定波長で吸光度を測定し、メラニン量を算出した。その結果、エクソソーム画分を添加して5日後に、PBSを添加したコントロールに対して、メラニン産生が促進傾向にあることを確認した(図7)。
(7) Effects of keratinocyte-derived exosomes on melanin production by melanocytes
After completion of the culture in the 6-well plate, the cells were washed with PBS, and the cells were collected in an Eppendorf tube using a cell scraper. After adding 150 μL of 2M NaOH to each Eppendorf tube, the cells were lysed at 100 ° C., and the supernatant obtained by centrifugation was measured for absorbance at a measurement wavelength of 405 nm to calculate the amount of melanin. As a result, 5 days after the addition of the exosome fraction, it was confirmed that melanin production tended to be accelerated compared to the control to which PBS was added (FIG. 7).
以上のことより、ケラチノサイトが恒常的に分泌しているエクソソームがメラノサイトの細胞活性及びメラニン産生能を正に制御していることが示された。 From the above, it was shown that the exosome secreted by keratinocytes positively controls the cellular activity and melanin production ability of melanocytes.
実施例１ エクソソーム放出抑制剤GW4869によるメラニン産生の抑制
（１）細胞培養
正常ヒト新生児包皮由来表皮角化細胞(凍結NHEK (F) Lightly; ケラチノサイト)、表皮角化細胞用増殖培地(Epilife)はLife Technologies社より、その培地用増殖添加剤(Humedia-KG)はクラボウ社より購入し、また、正常ヒト新生児包皮由来表皮メラニン細胞(凍結NHEM (NB) Darkly; メラノサイト)、表皮メラニン細胞用増殖培地(Medium254)、その培地用増殖添加剤(HMGS)はLife Technologies社より購入した。ケラチノサイト及びメラノサイトは、37℃ 5Vol%CO2の環境下で培養した。
Example 1 Suppression of melanin production by exosome release inhibitor GW4869 (1) Cell culture Normal human neonatal foreskin-derived epidermal keratinocytes (frozen NHEK (F) Lightly; keratinocytes), epidermal keratinocyte growth medium (Epilife) is Life From Media Technologies, the growth additive for media (Humedia-KG) was purchased from Kurabo Industries, and normal human neonatal foreskin-derived epidermal melanocytes (frozen NHEM (NB) Darkly; melanocytes), growth media for epidermal melanocytes ( Medium254) and its growth additive (HMGS) were purchased from Life Technologies. Keratinocytes and melanocytes were cultured in an environment of 37 ° C. and 5 Vol% CO 2 .
（２）エクソソーム放出抑制剤GW4869がケラチノサイトのエクソソーム放出量に及ぼす影響
ケラチノサイトを1.5×106 cells/flask (25mL/flask)の細胞密度で175cm2 flaskに播種した。この時の培地としては、ヒト上皮細胞成長因子(hEGF; Human Epidermal Growth Factor) 以外のHumedia-KG増殖添加剤（インスリン、ハイドロコーチゾン、BPE、ゲンタマイシン/アンフォテリシンB）を含むEpilife培地を使用した。播種した翌日に、エクソソームの放出抑制剤であるNeutral Sphingomyelinaseの阻害剤GW4869 (Sigma Aldrich)を終濃度で20μM（溶媒はDMSO）になるように添加し、37℃、5Vol%CO2の条件下で3日間培養を行った。コントロールとしては、同量のDMSOを添加した。培養終了後、細胞の培養上清から既に記載した遠心分離法によりエクソソーム画分を単離した。培養上清を除去した後に、底面に接着している細胞に対してプロナーゼ溶液(極東製薬工業)処理を施して、細胞接着を剥離した後に回収し、血球計算板を用いて細胞数のカウントを行った。また、エクソソーム画分についてBovine Serum Albumin (BSA)を標準物質としたBCA（ビシンコニン酸）法によりタンパク質定量を行い、それを細胞数で除することにより、1細胞あたりのエクソソーム放出量を算出した。その結果、GW4869の添加により、DMSOを添加したコントロールに対して、その放出量が有意に減少することが確認された(図8)。
(2) Effect of exosome release inhibitor GW4869 on exosome release of keratinocytes Keratinocytes were seeded in a 175 cm 2 flask at a cell density of 1.5 × 10 6 cells / flask (25 mL / flask). As the medium at this time, an Epilife medium containing Humedia-KG growth additives (insulin, hydrocortisone, BPE, gentamicin / amphotericin B) other than human epidermal growth factor (hEGF) was used. The day after seeding, add GW4869 (Sigma Aldrich), an inhibitor of exosome release inhibitor Neutral Sphingomyelinase, to a final concentration of 20 μM (solvent is DMSO), and under conditions of 37 ℃ and 5Vol% CO 2 Culture was performed for 3 days. As a control, the same amount of DMSO was added. After completion of the culture, the exosome fraction was isolated from the cell culture supernatant by the centrifugation method already described. After removing the culture supernatant, the cells adhering to the bottom surface are treated with pronase solution (Kyokuto Pharmaceutical Co., Ltd.), the cell adhesion is peeled off and collected, and the cell count is counted using a hemocytometer. went. The exosome fraction was subjected to protein quantification by the BCA (bicinchoninic acid) method using Bovine Serum Albumin (BSA) as a standard substance, and divided by the number of cells to calculate the amount of exosome released per cell. As a result, it was confirmed that the amount of release was significantly reduced by the addition of GW4869 relative to the control to which DMSO was added (FIG. 8).
（３）エクソソーム放出抑制剤GW4869がケラチノサイト及びメラノサイトからなる共培養系においてメラニン産生に及ぼす影響
ケラチノサイトを6-well plateに1×105cells/well (2 mL/well)の細胞密度で播種し、翌日、メラノサイトを2×105cells/well (1 mL/well)の細胞密度で播種した。さらにその翌日に、GW4869を終濃度で5、10、20 μMになるように添加し、37℃、5Vol%CO2の条件下で7日間培養を行った。培地には、試験用培地としてhEGF以外のHumedia-KG増殖添加剤（インスリン、ハイドロコーチゾン、BPE、ゲンタマイシン/アンフォテリシンB）を含むEpilife培地を用いた。コントロールとしては、同量のDMSOを添加した。なお、培地交換は3日に1度行った。培養終了後、細胞をPBSで洗浄し、RIPA buffer (Sigma-Aldrich)を用いて回収してから、超音波処理により細胞を破砕した。その後、15,000rpmで15分間遠心分離し、その上清についてBovine Serum Albumin (BSA)を標準物質としたBCA（ビシンコニン酸）法によりタンパク量を定量した後、各群のタンパク質量を揃え、定法に従ってSDS-PAGE及びウェスタンブロットに供した。一次抗体はanti-Pmel17 (Dako, 1:250)を用いた。二次抗体は、anti-mouse IgG, HRP-Linked F(ab’)2 Fragment Sheep (GE Healthcare Life Science)を用いた。 その後、ECL plus western blotting detection reagents (GE healthcare bioscience)を用いて発色させ、LAS4000 (GE healthcare bioscience)を用いて発現量を可視化した。内部標準としてのβ-actinの発現は、monoclonal antibody specific for β-actin (Sigma-Aldrich, 1:5000)を用いて評価した。Pmel17の検出バンドの強度を画像解析により定量した結果、DMSOを添加したコントロールに対して、GW4869を20μM処理した際に、それが有意に発現低下していることを確認した(図9)。Pmel17はメラノソームに特異的なタンパク質であることから、GW4869処理によりメラニン量が減少したものと考えられる。
(3) Effect of exosome release inhibitor GW4869 on melanin production in a co-culture system consisting of keratinocytes and melanocytes Seeding keratinocytes on a 6-well plate at a cell density of 1 × 10 5 cells / well (2 mL / well) The next day, melanocytes were seeded at a cell density of 2 × 10 5 cells / well (1 mL / well). The next day, GW4869 was added to a final concentration of 5, 10, and 20 μM, and the cells were cultured for 7 days under conditions of 37 ° C. and 5Vol% CO 2 . As the culture medium, Epilife medium containing Humedia-KG growth additives (insulin, hydrocortisone, BPE, gentamicin / amphotericin B) other than hEGF was used as a test medium. As a control, the same amount of DMSO was added. The medium was exchanged once every 3 days. After completion of the culture, the cells were washed with PBS, collected using RIPA buffer (Sigma-Aldrich), and then disrupted by sonication. Thereafter, the mixture was centrifuged at 15,000 rpm for 15 minutes, and the supernatant was quantified by the BCA (bicinchoninic acid) method using Bovine Serum Albumin (BSA) as a standard substance. SDS-PAGE and Western blot were used. Anti-Pmel17 (Dako, 1: 250) was used as the primary antibody. As the secondary antibody, anti-mouse IgG, HRP-Linked F (ab ′) 2 Fragment Sheep (GE Healthcare Life Science) was used. Thereafter, color was developed using ECL plus western blotting detection reagents (GE healthcare bioscience), and the expression level was visualized using LAS4000 (GE healthcare bioscience). Expression of β-actin as an internal standard was evaluated using monoclonal antibody specific for β-actin (Sigma-Aldrich, 1: 5000). As a result of quantifying the intensity of the detection band of Pmel17 by image analysis, it was confirmed that the expression was significantly reduced when GW4869 was treated with 20 μM with respect to the control to which DMSO was added (FIG. 9). Since Pmel17 is a protein specific to melanosomes, it is considered that the amount of melanin was reduced by GW4869 treatment.
（４）エクソソーム放出抑制剤GW4869がメラノサイトの単独培養系においてメラニン産生に及ぼす影響
メラノサイトを2×105 cells/well (2 mL/well)の細胞密度で播種した。その翌日に、GW4869を終濃度で5、10、20 μMになるように添加し、37℃、5Vol%CO2の条件下で7日間培養を行った。培地には、試験用培地としてMedium254 (phorbol 12-myristate 13-acetate (PMA)及びbovine pituitary extract (BPE)不含）を用いた。コントロールとしては、同量のDMSOを添加した。なお、培地交換は3日に1度行った。培養終了後、細胞の培養プレートをPBSで洗浄し、セルスクレーパーを用いてエッペンドルフチューブに細胞を回収した。各エッペンドルフチューブに2M NaOHを150 μL加えた後100℃にて細胞を溶解させ、遠心処理によって得られた上清について405 nmの測定波長で吸光度を測定し、メラニン量を算出した。その結果、DMSOを添加したコントロールに対して、GW4869を添加した際にメラニン産生量に対する影響は確認されなかった(図10)。
(4) Effect of exosome release inhibitor GW4869 on melanin production in melanocyte single culture system Melanocytes were seeded at a cell density of 2 × 10 5 cells / well (2 mL / well). On the next day, GW4869 was added to a final concentration of 5, 10, and 20 μM, and the cells were cultured for 7 days under conditions of 37 ° C. and 5 Vol% CO 2 . Medium 254 (without phorbol 12-myristate 13-acetate (PMA) and bovine pituitary extract (BPE)) was used as the test medium. As a control, the same amount of DMSO was added. The medium was exchanged once every 3 days. After completion of the culture, the cell culture plate was washed with PBS, and the cells were collected in an Eppendorf tube using a cell scraper. After adding 150 μL of 2M NaOH to each Eppendorf tube, the cells were lysed at 100 ° C., and the supernatant obtained by centrifugation was measured for absorbance at a measurement wavelength of 405 nm to calculate the amount of melanin. As a result, when GW4869 was added to the control to which DMSO was added, no influence on melanin production was confirmed (FIG. 10).
（５）エクソソーム放出抑制剤GW4869が表皮メラニン量に及ぼす影響
米国スキンバンクNational Disease Research Interchange (NDRI)から、外科手術由来の正常ヒト皮膚組織を提供頂いた。ヒト皮膚組織は、皮下脂肪をトリミングした後に、ナイフで約1 cm×1 cmの大きさに小片化し、6-well plateを使用して37℃ 5Vol%CO2の環境下にて培養した。培養には、Fetal Bovine Serum (FBS)を10% (v/v)含むAdvanced DMEM培地 (いずれもLife Technologies)を使用した。ヒト皮膚組織を6-well plateに静置し、GW4869を終濃度で20 μMになるように培地中に添加した上で組織培養を実施した。2〜3日毎に培地を交換しながら、培養開始から7日間経過後に皮膚組織を回収、定法に従って凍結組織切片を作成後にフォンタナマッソン染色を実施し(図11A)、その染色像に関して、Image Jソフトウェアを用いて二値化を行うことにより、画像解析を行った。表皮と真皮の境界における単位長あたりの表皮メラニン量を算出した結果、DMSOを添加したコントロールに対して、GW4869を処理した皮膚では、有意にメラニン量が低下していることが確認された(図11B)。
(5) Effect of exosome release inhibitor GW4869 on epidermal melanin amount A normal human skin tissue derived from surgery was provided by the US skin bank National Disease Research Interchange (NDRI). The human skin tissue was trimmed into subcutaneous fat, then cut into pieces of about 1 cm × 1 cm with a knife, and cultured in an environment of 37 ° C. and 5 Vol% CO 2 using a 6-well plate. For the culture, Advanced DMEM medium containing 10% (v / v) Fetal Bovine Serum (FBS) (both Life Technologies) was used. The human skin tissue was allowed to stand on a 6-well plate, and GW4869 was added to the medium to a final concentration of 20 μM, and then tissue culture was performed. The skin tissue was collected 7 days after the start of culture while changing the medium every 2 to 3 days, and frozen tissue sections were prepared according to a conventional method, followed by Fontana Masson staining (Fig. 11A). Image analysis was performed by performing binarization using. As a result of calculating the amount of epidermal melanin per unit length at the boundary between the epidermis and dermis, it was confirmed that the amount of melanin was significantly decreased in the skin treated with GW4869 compared to the control to which DMSO was added (Fig. 11B).
以上のことより、GW4869はケラチノサイトに作用して、エクソソームの放出を抑制し、エクソソームによるメラノサイトの活性化を抑制させることで、メラニン産生を抑制したものと考えられる。 From the above, it is considered that GW4869 acts on keratinocytes to suppress the release of exosomes and suppress the activation of melanocytes by exosomes, thereby suppressing melanin production.
Claims (5)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014237995 | 2014-11-25 | ||
| JP2014237995 | 2014-11-25 | ||
| US201562235714P | 2015-10-01 | 2015-10-01 | |
| US62/235,714 | 2015-10-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016104735A true JP2016104735A (en) | 2016-06-09 |
| JP6688051B2 JP6688051B2 (en) | 2020-04-28 |
Family
ID=56101891
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015201569A Active JP6650240B2 (en) | 2014-11-25 | 2015-10-09 | Method of searching for melanin control agent |
| JP2015229880A Active JP6688051B2 (en) | 2014-11-25 | 2015-11-25 | Melanin production inhibitor |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015201569A Active JP6650240B2 (en) | 2014-11-25 | 2015-10-09 | Method of searching for melanin control agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP6650240B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170003000A (en) * | 2015-06-30 | 2017-01-09 | (주)아모레퍼시픽 | Composition for skin whitening and method for screening the skin whitening materials |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108699589B (en) * | 2016-07-08 | 2021-08-13 | 花王株式会社 | Method for preparing nucleic acid sample |
| CN107007541B (en) * | 2017-05-23 | 2020-11-13 | 北京希诺赛尔健康科技推广有限公司 | Application of exosome in skin whitening preparation |
| WO2019146612A1 (en) * | 2018-01-23 | 2019-08-01 | ノバセラ株式会社 | Composition for skin diseases treatment use |
| CN111110699B (en) * | 2020-04-01 | 2020-07-17 | 广州市新纪元化妆品有限公司 | Application of combination of polypeptide conjugate and epidermal stem cell exosome in medicines and cosmetics |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1192326A (en) * | 1997-09-22 | 1999-04-06 | Shiseido Co Ltd | Skin preparation for external use |
| JP2006273808A (en) * | 2005-03-30 | 2006-10-12 | Naris Cosmetics Co Ltd | Skin whitening cosmetic |
| JP2010189368A (en) * | 2009-02-18 | 2010-09-02 | Hiroyuki Iwasaki | Liquid external preparation for skin |
| WO2013054534A1 (en) * | 2011-10-14 | 2013-04-18 | 国立大学法人北海道大学 | DRUGS FOR DISEASES ASSOCIATED WITH AMYLOID β, AND SCREENING THEREFOR |
-
2015
- 2015-10-09 JP JP2015201569A patent/JP6650240B2/en active Active
- 2015-11-25 JP JP2015229880A patent/JP6688051B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1192326A (en) * | 1997-09-22 | 1999-04-06 | Shiseido Co Ltd | Skin preparation for external use |
| JP2006273808A (en) * | 2005-03-30 | 2006-10-12 | Naris Cosmetics Co Ltd | Skin whitening cosmetic |
| JP2010189368A (en) * | 2009-02-18 | 2010-09-02 | Hiroyuki Iwasaki | Liquid external preparation for skin |
| WO2013054534A1 (en) * | 2011-10-14 | 2013-04-18 | 国立大学法人北海道大学 | DRUGS FOR DISEASES ASSOCIATED WITH AMYLOID β, AND SCREENING THEREFOR |
Non-Patent Citations (2)
| Title |
|---|
| SCIENCE, vol. 319, JPN6019028763, 2008, pages 1244 - 1247, ISSN: 0004245005 * |
| 薬学雑誌, vol. 128, no. 8, JPN6019028762, 2008, pages 1203 - 1207, ISSN: 0004212082 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170003000A (en) * | 2015-06-30 | 2017-01-09 | (주)아모레퍼시픽 | Composition for skin whitening and method for screening the skin whitening materials |
| JP2018521038A (en) * | 2015-06-30 | 2018-08-02 | アモーレパシフィック コーポレーション | Skin whitening composition and method for screening skin whitening active substance |
| KR102394636B1 (en) | 2015-06-30 | 2022-05-09 | (주)아모레퍼시픽 | Composition for skin whitening and method for screening the skin whitening materials |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016103997A (en) | 2016-06-09 |
| JP6688051B2 (en) | 2020-04-28 |
| JP6650240B2 (en) | 2020-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6688051B2 (en) | Melanin production inhibitor | |
| JP6923927B2 (en) | Compositions for suppressing or ameliorating hair loss and whitening and their use | |
| JP5872158B2 (en) | Skin whitening method and screening method for skin spot formation inhibition and / or removal factor | |
| Coppe et al. | A role for fibroblasts in mediating the effects of tobacco-induced epithelial cell growth and invasion | |
| JP2020502078A (en) | Pharmaceutical composition containing mitochondria | |
| JP6584494B2 (en) | Method for inhibiting HMGB1 activation of melanin producing cells, and method for identifying a drug suitable for such inhibition | |
| EP2897976B1 (en) | Use of pedf-derived peptides for preventing and/or ameliorating skin aging | |
| US20230210928A1 (en) | Screening method for laminin 511 production promoting agent, basal epidermal layer stabilizing agent, and/or epidermal stem cells reduction inhibiting or proliferation promoting agent | |
| CN108139405B (en) | Use of EB1 as a biomarker of drug response | |
| JP6460426B2 (en) | Screening method for skin tone improver | |
| Na et al. | Isolation and characterization of outer root sheath melanocytes of human hair follicles | |
| JP6663690B2 (en) | Melanin production promoter | |
| US20190055560A1 (en) | Fats as a target for treating tumors and uses thereof | |
| CA2360762C (en) | Sebocytes, sebocyte cell lines and applications thereof | |
| CN112089638B (en) | Composition for inhibiting melanin synthesis | |
| TW201334773A (en) | Compounds and pharmaceutical compositions thereof for inhibiting mammalian tumor cell proliferation | |
| US20200352954A1 (en) | Methods of treating age-related symptoms in mammals and compositions therefor | |
| Luo et al. | Junctional E-cadherin/p120-catenin is correlated with the absence of supporting cells to hair cells conversion in postnatal mice cochleae | |
| KR102256277B1 (en) | Composition for Suppressing Cutaneous Pigmentation Containing Rab5A Inhibitors | |
| Sobiepanek et al. | Soszy nska | |
| Chen et al. | Functional expression of cystic fibrosis transmembrane conductance regulator in rat oviduct epithelium | |
| WO2021147740A1 (en) | Use of mapk/erk pathway inhibitor in antagonizing skin aging and radiation-induced premature aging | |
| US20230053307A1 (en) | Method for preventing or treating skin disorders and conditions | |
| JP2010159252A (en) | Melanosome traffick inhibitor, and method for the same | |
| Sanchez Hanke et al. | In vitro isolation and cell culture of vestibular inner ear melanocytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180918 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190730 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200221 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200331 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200403 |
|
| R151 | Written notification of patent or utility model registration |
Ref document number: 6688051 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |